Clinical Trial Update: Growth Hormone Therapy in Osteogenesis Imperfecta [Phase 3]

View source ↗

Summary

A Phase 3 trial of growth hormone therapy for osteogenesis imperfecta has completed and posted results in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteogenesis Imperfecta

Drugs mentioned

• Somatropin (somatropin)

Snippet

Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Conditions: Osteogenesis Imperfecta | Phase 3 | Status: COMPLETED | Results posted: 2019-01-29